Abstract: A method is described for detecting a target nucleic acid, in which the target nucleic acid is amplified in the presence of a proofreading DNA polymerase and an allele-specific reactive primer (ASRP) including (i) a nucleotide sequence complementary to the target nucleic acid and (ii) modified nucleotide(s) located in a region from a nucleotide located right before a non-complementary nucleotide on the 5?-side of the non-complementary nucleotide, so that an amplification product of the target nucleic acid is produced when the ASRP is complementary to the target nucleic acid, and so that when the ASRP is not complementary to the target nucleic acid, an amplification product of the target nucleic acid will not be produced. The detection method has a very high specificity of amplification, and is useful for applications such as detecting mutations, detecting methylation of CpG after bisulfite treatment, and detecting target DNA from a DNA library.

Abstract: The present invention relates to the novel use of syndecan-2 (SDC2; NM_002998) gene as a gastric polyp- and gastric cancer-specific methylation biomarker, and more particularly, to the use of the syndecan-2 gene as a biomarker that enables gastric polyp and gastric cancer to be diagnosed in an early stage by measuring the methylation level thereof. The present invention has an effect in that the methylation of the CpG island of the gastric polyp- and gastric cancer-specific marker gene can be detected to thereby provide information for diagnosing gastric cancer. The use of the methylation detection method according to the present invention or the diagnostic composition, kit or nucleic acid chip according to the present invention makes it possible to diagnose gastric cancer at an early transformation stage, thus enabling the early diagnosis of gastric cancer.

Abstract: The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.

Abstract: The present invention relates to a method for producing a DNA chip, which comprises the steps of: (a) cloning a probe, where a linker is coupled to one or both ends of an oligonucleotide to be integrated on a slide, into a vector; (b) transforming host cells with the vector; (c) culturing the transformed host cells, to recover the probe where the linker is coupled to one or both ends of the oligonucleotides; and (d) integrating the recovered double-helical probes on a slide. Also, the present invention relates to a DNA chip for HPV diagnosis produced by the method, and a method for diagnosing the presence or genotype of HPV using the DNA chip.

Abstract: A method for detecting the methylation of promoters using HpaII, a methylation-sensitive restriction enzyme. In such method, DNAs, derived from clinical samples or subjects to be diagnosed, are cut with HpaII, the cut DNAs are amplified by PCR with primers capable of amplifying CpG islands, and the presence or absence of the PCR amplification products is determined using a DNA chip for methylation detection. Unlike prior approaches, the inventive method allows the methylation of gene promoters to be detected in a simple and economical manner, and thus is useful for the diagnosis of diseases such as cancer that are characterized by methylation of gene promoters.